TickerFacts.

Phathom Pharmaceuticals, Inc. (PHAT): Revenue

Annual figures by period end, from SEC filings.

$175.11M
Year ended 2025-12-31
$239.66M
Trailing 12 months to 2026-06-30
2022-12-31: $02023-12-31: $682.0K2024-12-31: $55.25M2025-12-31: $175.11M$175.11M
2022-12-31 Revenue (USD) 2025-12-31
Period endedRevenueChange YoYSource filing
2025-12-31$175.11M+216.9%2026-02-26, From 2025-01-01
2024-12-31$55.25Mn/m2026-02-26, From 2024-01-01
2023-12-31$682.0Kn/a2025-03-06, From 2023-01-01
2022-12-31$0n/a2024-06-14, From 2022-01-01

Revenue at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedRevenueChange YoY
Phathom Pharmaceuticals, Inc. (PHAT)2025-12-31$175.11M+216.9%
Cryoport, Inc. (CYRX)2025-12-31$176.18M+12.4%
Syndax Pharmaceuticals Inc (SNDX)2025-12-31$172.35M+627.8%
Lifevantage Corp (LFVN)2026-06-30$182.59M-20.1%
Stoke Therapeutics, Inc. (STOK)2025-12-31$184.42M+404.5%
Maravai Lifesciences Holdings, Inc. (MRVI)2025-12-31$185.74M-28.3%
Rhythm Pharmaceuticals, Inc. (RYTM)2025-12-31$189.76M+45.8%
Liquidia Corp (LQDA)2025-12-31$158.32Mn/m
Heron Therapeutics, Inc. (HRTX)2025-12-31$154.90M+7.4%

Compare PHAT, CYRX, SNDX, LFVN side by side · Screen every company in Pharmaceutical Preparations ↗